Form 13-F position report

ACLARIS THERAPEUTICS INC

Reported by MORGAN STANLEY

ACRS CUSIP 00461U105 Manager CIK 0000895421

Reported 140,404 shares, down 27,408 (16.3%) from the prior quarter.

Reported value -16.3%; share count -16.3% vs. the prior quarter.

Reduced
% of reported 13F value < 0.01% This manager · Q4 2022
Shares 140,404 Quarter-end amount reported
Reported value $2,211,364 Fair value at quarter end
Consecutive quarters held 29 Through Q4 2022

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 621000
2022-03-31 532000
2022-06-30 2249000
2022-09-30 2641000
2022-12-31 2211364
2023-03-31 5473840
2023-06-30 16953031
2023-09-30 11633979
2023-12-31 1024674
2024-03-31 609665
2024-06-30 204977
2024-09-30 552889
2024-12-31 2658025
2025-03-31 3695843
2025-06-30 5027072
2025-09-30 7746768
2025-12-31 10280323
2026-03-31 10298633
2026-06-30 709477
2026-09-30 1294459

Quarterly position history

How this manager's reported quarter-end position changed over time.

20 quarters
Quarterly reported position history for ACLARIS THERAPEUTICS INC held by MORGAN STANLEY.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Added 246,095 +111,978 (83.5%) < 0.01% $1,294,459 2026-11-13
Q2 2026 Reduced 134,117 -2,612,185 (-95.1%) < 0.01% $709,477 2026-08-13
Q1 2026 Reduced 2,746,302 -669,088 (-19.6%) < 0.01% $10,298,633 2026-05-15
Q4 2025 Reduced 3,415,390 -661,856 (-16.2%) < 0.01% $10,280,323 2026-02-13
Q3 2025 Added 4,077,246 +537,054 (15.2%) < 0.01% $7,746,768 2025-11-14
Q2 2025 Added 3,540,192 +1,124,608 (46.6%) < 0.01% $5,027,072 2025-08-15
Q1 2025 Added 2,415,584 +1,343,800 (125.4%) < 0.01% $3,695,843 2025-05-15
Q4 2024 Added 1,071,784 +591,011 (122.9%) < 0.01% $2,658,025 2025-02-14
Q3 2024 Added 480,773 +294,430 (158.0%) < 0.01% $552,889 2024-11-14
Q2 2024 Reduced 186,343 -305,323 (-62.1%) < 0.01% $204,977 2024-08-14
Q1 2024 Reduced 491,666 -484,213 (-49.6%) < 0.01% $609,665 2024-05-15
Q4 2023 Reduced 975,879 -722,512 (-42.5%) < 0.01% $1,024,674 2024-02-13
Q3 2023 Added 1,698,391 +63,576 (3.9%) < 0.01% $11,633,979 2023-11-15
Q2 2023 Added 1,634,815 +958,197 (141.6%) < 0.01% $16,953,031 2023-08-14
Q1 2023 Added 676,618 +536,214 (381.9%) < 0.01% $5,473,840 2023-05-15
Q4 2022 Reduced 140,404 -27,408 (-16.3%) < 0.01% $2,211,364 2023-02-14
Q3 2022 Added 167,812 +6,702 (4.2%) < 0.01% $2,641,000 2022-11-14
Q2 2022 Added 161,110 +130,171 (420.7%) < 0.01% $2,249,000 2022-08-15
Q1 2022 Reduced 30,939 -11,806 (-27.6%) < 0.01% $532,000 2022-05-13
Q4 2021 Added 42,745 +10,303 (31.8%) < 0.01% $621,000 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

140 managers reported ACLARIS THERAPEUTICS INC for Q4 2022.

Managers reporting ACLARIS THERAPEUTICS INC in Q4 2022.
Manager Activity Shares Change % of reported 13F Reported value Tenure
WELLINGTON MANAGEMENT GROUP LLP Added 5,484,013 +2,030,160 0.02% $86,373,206 8 qtrs
BlackRock Inc Added 5,088,659 +278,361 < 0.01% $80,146,383 28 qtrs
VR Adviser LLC Unchanged 4,563,962 0 12.11% $71,882,402 9 qtrs
RA CAPITAL MANAGEMENT L P Unchanged 4,398,453 0 1.4% $69,275,635 4 qtrs
Rock Springs Capital Management LP Unchanged 3,961,249 0 1.5% $62,389,672 29 qtrs
BVF INC IL Reduced 3,276,543 -700,000 2.18% $51,605,552 7 qtrs
VANGUARD GROUP INC Added 3,122,255 +190,546 < 0.01% $49,175,517 29 qtrs
Foresite Capital Management IV LLC Unchanged 2,808,034 0 18.89% $44,226,536 10 qtrs
ORBIMED ADVISORS LLC Unchanged 2,758,434 0 0.84% $43,445,336 7 qtrs
BRAIDWELL LP New 2,393,985 +2,393,985 1.26% $37,705,264 1 qtr
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
December 31, 2022
Filed
February 14, 2023
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
130,103
Shared
1,071
None
9,230

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.